What's Going On With Eli Lilly Stock Friday? - Eli Lilly (NYSE:LLY)

What's Going On With Eli Lilly Stock Friday? - Eli Lilly (NYSE:LLY)

Eli Lilly and Co. (NYSE:LLY) on Friday shared updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for previously treated breast cancer patients. The trial included patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer (MBC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. As monotherapy,…

New Eli Lilly Results Suggest Major Delay To Chemotherapy For Breast Cancer Patients

Eli Lilly and Co. (NYSE:LLY) on Friday shared updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant) for previously treated breast cancer patients. The trial included patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2–negative (HER2–)…

Eli Lilly (NYSE: LLY) Inluriyo data show 38% risk cut, delay chemo in ER+ HER2– MBC

Phase 3 EMBER-3 data show Inluriyo improved median OS 11.4 months vs endocrine therapy, while adding Verzenio cut progression/death 41% and delayed chemo.